Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Livanova Plc's Business Segments
Livanova Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
3
Largest Segment
Cardiopulmonary
Total Revenue
$ 362
Regions Reported
2
Revenue Share by Reportable Segment - Q1 FY2026
- Cardiopulmonary57.7%
- Neuromodulation42%
- Corporate and Unallocated0.5%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Cardiopulmonary | $ 209 | 57.7% |
| Neuromodulation | $ 152 | 42% |
| Corporate and Unallocated | $ 2 | 0.5% |
Revenue Share by Region - Q1 FY2026
- Locations Excluding the United States and Europe28.2%
- Europe20.9%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Locations Excluding the United States and Europe | $ 102 | 28.2% |
| Europe | $ 76 | 20.9% |
Description of Livanova Plc
Livanova Plc is a diversified medical technology company that is committed to improving patient outcomes and reducing the cost of healthcare in the areas of cardiovascular and neuromodulation treatment. The company was formed in 2015, as a result of a merger between Cyberonics Inc. and Sorin Group.
Headquartered in London, Livanova operates in over 100 countries worldwide, with its primary focus being on the development, manufacture, and marketing of medical devices used in the treatment of various heart and neurological conditions. It has over 3,500 employees working across its various manufacturing and research facilities in the United States, Europe, and Asia-Pacific.
Livanova’s Cardiovascular business segment offers a range of products that include heart-lung equipment, oxygenators, perfusion systems, cannulae, and devices used in extracorporeal membrane oxygenation (ECMO) therapy. Its pioneering ECMO technology is widely recognized and used for treating life-threatening cardiopulmonary failure in neonatal and pediatric patients. The company’s implantable cardiac rhythm management products, including pacemakers, defibrillators, and cardiac resynchronization therapy devices, are designed to manage cardiac arrhythmias and heart failure.
The Neuromodulation business segment of Livanova provides products for the treatment of patients with epilepsy, depression, chronic pain, and other neurological disorders. Its Vagus Nerve Stimulation (VNS) Therapy System is a revolutionary device that delivers electrical stimulation to the vagus nerve, offering relief to patients with epilepsy and depression who have not responded to traditional treatments. The segment also produces Deep Brain Stimulation (DBS) Systems, which can reduce symptoms of movement disorders such as Parkinson’s disease.
Livanova Plc is dedicated to research and development, with a strong pipeline of new products and technological innovation. They continually invest in research and development and have a strong focus on profitability and growth. They have a strong corporate culture, and their core values include focusing on patients, working collaboratively, continuous improvement, and maintaining a high level of ethical conduct.
In conclusion, Livanova Plc is a global leader in the development and manufacture of medical technology that improves the lives of people with heart and neurological conditions. With a dedicated team, strong product pipeline, and a commitment to innovation, Livanova is well-positioned to grow in the medical device market for many years to come.
Headquartered in London, Livanova operates in over 100 countries worldwide, with its primary focus being on the development, manufacture, and marketing of medical devices used in the treatment of various heart and neurological conditions. It has over 3,500 employees working across its various manufacturing and research facilities in the United States, Europe, and Asia-Pacific.
Livanova’s Cardiovascular business segment offers a range of products that include heart-lung equipment, oxygenators, perfusion systems, cannulae, and devices used in extracorporeal membrane oxygenation (ECMO) therapy. Its pioneering ECMO technology is widely recognized and used for treating life-threatening cardiopulmonary failure in neonatal and pediatric patients. The company’s implantable cardiac rhythm management products, including pacemakers, defibrillators, and cardiac resynchronization therapy devices, are designed to manage cardiac arrhythmias and heart failure.
The Neuromodulation business segment of Livanova provides products for the treatment of patients with epilepsy, depression, chronic pain, and other neurological disorders. Its Vagus Nerve Stimulation (VNS) Therapy System is a revolutionary device that delivers electrical stimulation to the vagus nerve, offering relief to patients with epilepsy and depression who have not responded to traditional treatments. The segment also produces Deep Brain Stimulation (DBS) Systems, which can reduce symptoms of movement disorders such as Parkinson’s disease.
Livanova Plc is dedicated to research and development, with a strong pipeline of new products and technological innovation. They continually invest in research and development and have a strong focus on profitability and growth. They have a strong corporate culture, and their core values include focusing on patients, working collaboratively, continuous improvement, and maintaining a high level of ethical conduct.
In conclusion, Livanova Plc is a global leader in the development and manufacture of medical technology that improves the lives of people with heart and neurological conditions. With a dedicated team, strong product pipeline, and a commitment to innovation, Livanova is well-positioned to grow in the medical device market for many years to come.
Livanova Plc is a global leader in the medical device industry, focusing on the development and manufacturing of innovative solutions aimed at improving patient care and quality of life. The company has established itself as a key player in medical devices primarily targeting cardiovascular and neurological disorders. Heres an extensive overview of the segments, products, and services offered by Livanova Plc:
Segments
1. Cardiac Surgery:
Livanova is deeply involved in the cardiac surgery segment, providing technology and devices that assist in various types of heart surgeries. Key offerings in this segment include:
- Cardiopulmonary Bypass Systems: These systems include heart-lung machines and oxygenators that support patients during open-heart surgery by maintaining circulation and oxygenation.
- Autotransfusion Systems: Designed to minimize blood loss during surgery, these systems allow for the collection and reinfusion of a patients blood.
2. Cardiac Rhythm Management:
This segment addresses the growing need for devices that regulate heart rhythms and prevent life-threatening conditions:
- Implantable Cardiac Devices: Livanova offers state-of-the-art pacemakers and implantable cardioverter defibrillators (ICDs) that are designed to treat arrhythmias and prevent sudden cardiac arrest.
- Remote Monitoring Solutions: These technologies enable healthcare providers to monitor patients devices remotely, enhancing patient safety and response times.
3. Neuromodulation:
In this segment, Livanova focuses on devices that modify nerve activity to treat a variety of neurological conditions:
- Vagus Nerve Stimulation (VNS): This therapy is particularly significant for patients with epilepsy and treatment-resistant depression, offering a non-pharmacological option to improve symptoms.
- Chronic Pain Management: Technologies aimed at alleviating chronic pain conditions through targeted neurostimulation.
4. Surgical Robotics:
Livanova is also pioneering advancements in minimally invasive surgical techniques through robotic systems:
- Robotic-Assisted Surgery: These systems facilitate precise surgical interventions, leading to reduced recovery times, less postoperative pain, and lower rates of complications.
Products
1. Perceval Aortic Valve:
This innovative sutureless aortic valve replacement device allows for rapid implantation without traditional suturing techniques. This technology is designed to minimize surgical trauma and enhance patient recovery.
2. Pulsatile Flow Pumps:
These pumps provide critical extracorporeal circulation during cardiac procedures, helping maintain blood flow and oxygenation while the heart is being operated on.
3. VNS Therapy:
Livanovas proprietary Vagus Nerve Stimulation device is a groundbreaking solution for patients suffering from drug-resistant epilepsy and severe depression. The implantable device sends electrical impulses to the vagus nerve, helping to regulate abnormal brain activity.
4. CyberKnife:
The CyberKnife system represents a breakthrough in cancer treatment, utilizing advanced robotic technology and image-guidance to deliver precisely targeted radiation therapy to tumors without damaging surrounding healthy tissue.
Services
1. Patient Management and Support:
Livanova offers comprehensive patient management services designed to support those living with chronic conditions. This includes personalized education, counseling, and clinical support to improve adherence to treatment protocols.
2. Technical Support:
The company provides extensive technical assistance for its products, ensuring optimal functionality and addressing any operational concerns that might arise.
3. Training and Education:
Livanova is committed to educating healthcare professionals on best practices for using its medical devices. The training programs encompass hands-on workshops, seminars, and online resources, ensuring practitioners are well-prepared to provide the best care.
4. Clinical Research and Development:
Livanova prioritizes innovation through ongoing clinical research. The company engages in rigorous studies to assess the safety and efficacy of its products, contributing valuable data to the medical community and advancing treatment options.
Conclusion
Overall, Livanova Plc offers a comprehensive suite of segments, products, and services that are integral to enhancing patient care across cardiovascular and neurological disciplines. The company’s dedication to research, technological advancement, and clinical excellence underscores its position as a key player in the medical device industry, committed to improving health outcomes and enriching the lives of patients globally.
Segments
1. Cardiac Surgery:
Livanova is deeply involved in the cardiac surgery segment, providing technology and devices that assist in various types of heart surgeries. Key offerings in this segment include:
- Cardiopulmonary Bypass Systems: These systems include heart-lung machines and oxygenators that support patients during open-heart surgery by maintaining circulation and oxygenation.
- Autotransfusion Systems: Designed to minimize blood loss during surgery, these systems allow for the collection and reinfusion of a patients blood.
2. Cardiac Rhythm Management:
This segment addresses the growing need for devices that regulate heart rhythms and prevent life-threatening conditions:
- Implantable Cardiac Devices: Livanova offers state-of-the-art pacemakers and implantable cardioverter defibrillators (ICDs) that are designed to treat arrhythmias and prevent sudden cardiac arrest.
- Remote Monitoring Solutions: These technologies enable healthcare providers to monitor patients devices remotely, enhancing patient safety and response times.
3. Neuromodulation:
In this segment, Livanova focuses on devices that modify nerve activity to treat a variety of neurological conditions:
- Vagus Nerve Stimulation (VNS): This therapy is particularly significant for patients with epilepsy and treatment-resistant depression, offering a non-pharmacological option to improve symptoms.
- Chronic Pain Management: Technologies aimed at alleviating chronic pain conditions through targeted neurostimulation.
4. Surgical Robotics:
Livanova is also pioneering advancements in minimally invasive surgical techniques through robotic systems:
- Robotic-Assisted Surgery: These systems facilitate precise surgical interventions, leading to reduced recovery times, less postoperative pain, and lower rates of complications.
Products
1. Perceval Aortic Valve:
This innovative sutureless aortic valve replacement device allows for rapid implantation without traditional suturing techniques. This technology is designed to minimize surgical trauma and enhance patient recovery.
2. Pulsatile Flow Pumps:
These pumps provide critical extracorporeal circulation during cardiac procedures, helping maintain blood flow and oxygenation while the heart is being operated on.
3. VNS Therapy:
Livanovas proprietary Vagus Nerve Stimulation device is a groundbreaking solution for patients suffering from drug-resistant epilepsy and severe depression. The implantable device sends electrical impulses to the vagus nerve, helping to regulate abnormal brain activity.
4. CyberKnife:
The CyberKnife system represents a breakthrough in cancer treatment, utilizing advanced robotic technology and image-guidance to deliver precisely targeted radiation therapy to tumors without damaging surrounding healthy tissue.
Services
1. Patient Management and Support:
Livanova offers comprehensive patient management services designed to support those living with chronic conditions. This includes personalized education, counseling, and clinical support to improve adherence to treatment protocols.
2. Technical Support:
The company provides extensive technical assistance for its products, ensuring optimal functionality and addressing any operational concerns that might arise.
3. Training and Education:
Livanova is committed to educating healthcare professionals on best practices for using its medical devices. The training programs encompass hands-on workshops, seminars, and online resources, ensuring practitioners are well-prepared to provide the best care.
4. Clinical Research and Development:
Livanova prioritizes innovation through ongoing clinical research. The company engages in rigorous studies to assess the safety and efficacy of its products, contributing valuable data to the medical community and advancing treatment options.
Conclusion
Overall, Livanova Plc offers a comprehensive suite of segments, products, and services that are integral to enhancing patient care across cardiovascular and neurological disciplines. The company’s dedication to research, technological advancement, and clinical excellence underscores its position as a key player in the medical device industry, committed to improving health outcomes and enriching the lives of patients globally.